Skip to content
sellModerate

Yoshiyuki Aikawa sold $9.4M of SBC

Chairman and CEO at SBC Medical Group Holdings Inc. 3,100,000 shares at an average of $3.02, traded Apr 21, 2026, filed Apr 23, 2026.

Warning score
50
Value
$9.4M
3,100,000 shares
Holdings after
79,304,460
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $9.4M at market
    +25
  • Share of holdings sold
    Sold 3.8% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -9.7%, 3m -13.8%, 6m -.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SBCOct 9, 2026 · close 5.42
Since filing Apr 23, 2026: +59.4%SPY +10.5% · excess +49.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001493152-26-018813, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Apr 21, 2026SOpen-market sale
Common Stock
-3,100,000$3.02$9.4M79,304,460Apr 23, 2026

Related signals

Other insiders at SBC Medical Group Holdings Inc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
50Moderate
SBCsell
SBC Medical Group Holdings Inc
Yoshiyuki Aikawa
Chairman and CEO
$1.4M
465,000 shares
-1%
70Notable
SBCsell
SBC Medical Group Holdings Inc
Yoshiyuki Aikawa
Chairman and CEO
$9.4M
4,422,900 shares
-84%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.